<![CDATA[FDA Grants Breakthrough Therapy Designation for Ulizacaltamine in Essential Tremor ]]>
Announced on December 29, 2025, by Praxis Precision Medicines Inc., the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ulixacaltamine for the treatment of patients with essential tremor.1 “The granting of the …